Two medicines, side by side
Aclidinium vs amiodarone
Aclidinium is labeled for copd; amiodarone has no indication this site maps. Their labels share no use, so they are not alternatives to each other. Drugs@FDA records approvals of aclidinium since 2012 and of amiodarone since 1985. Pharmacies paid $344.55 per unit (Tudorza pressair 400 mcg inhal) and $0.122 per amiodarone HCl 200 mg tablet (NADAC, October 7, 2026); the strengths differ and one is a brand and one a generic, so the two prices are not like for like. In FDA's classes, aclidinium is an anticholinergic and amiodarone an antiarrhythmic.
Check it at the source: the aclidinium FDA label on DailyMed (effective August 1, 2022); the amiodarone FDA label on DailyMed (effective December 9, 2025).
Highlights of the aclidinium record
Aclidinium (Tudorza Pressair) · label of August 1, 2022
Used for
From the label: indicationsTUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). TUDORZA PRESSAIR is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
On the market
- Earliest approval on file
- July 23, 2012
- Generic labelers
- none listed
- Pharmacy cost
- $344.55 per unit
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the amiodarone record
Amiodarone (Pacerone) · label of December 9, 2025
PULMONARY, HEPATIC AND CARDIAC TOXICITY Amiodarone hydrochloride is intended for use only in patients with the indicated life-threatening arrhythmias because its use is accompanied by substantial toxicity [see Indications and Usage (1) ]. Amiodarone hydrochloride can cause pulmonary toxicity (hypersensitivity pneumonitis or interstitial/alveolar pneumonitis) that has resulted in clinically manifest disease at rates as high as 17% in some series of patients.
Used for
From the label: indicationsAmiodarone hydrochloride is indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. Amiodarone hydrochloride is an antiarrhythmic indicated for: Recurrent ventricular fibrillation. […]
On the market
- Earliest approval on file
- December 24, 1985
- Generic labelers
- 32 labelers
- Pharmacy cost
- $0.122 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 7
Source: FDA drug labels via openFDA (Aclidinium label of August 1, 2022, Amiodarone label of December 9, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do aclidinium and amiodarone differ on the record?
In FDA's classes, aclidinium is an anticholinergic and amiodarone an antiarrhythmic.
How each works, in its label's words: Aclidinium, “It has similar affinity to the subtypes of muscarinic receptors M 1 to M 5 .”; Amiodarone, “Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes.”
Half-life, in each label's words: Aclidinium, “After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose and the estimated effective …”; Amiodarone, “Elimination Following single dose administration in 12 healthy subjects, amiodarone exhibited multi- compartmental …”
Only the amiodarone label carries a boxed warning.
Generics: aclidinium none approved; amiodarone since 1998 (Drugs@FDA).
| Aclidinium | Amiodarone | |
|---|---|---|
| Labeled for | COPD | n/a |
| Pharmacologic class | Anticholinergic | Antiarrhythmic |
| How it works (label) | Aclidinium bromide is a long-acting antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors M 1 to M 5 . | Amiodarone is considered a class III antiarrhythmic drug, but it possesses electrophysiologic characteristics of all four Vaughan Williams classes. |
| Half-life (label) | After dry powder inhalation, urinary excretion of aclidinium is about 0.09% of the dose and the estimated effective half-life is 5 to 8 hours. | Elimination Following single dose administration in 12 healthy subjects, amiodarone exhibited multi- compartmental pharmacokinetics with a mean apparent plasma terminal elimination half-life of 58 days (range 15 to 142 … |
| Earliest approval on file (Drugs@FDA) | July 23, 2012 | December 24, 1985 |
| First generic approved | none | April 30, 1998 |
| Generic labelers (NDC) | none listed | 32 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $344.55 per unit (Tudorza pressair 400 mcg inhal) | $0.122 per tablet (Amiodarone HCl 200 mg tablet) |
| 12-month price change | n/a | +4% |
| Boxed warning | No | Yes |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 7 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,373 | 11,139 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Aclidinium label, drug interactionsAvoid administrations of TUDORZA PRESSAIR with other anticholinergic-containing drugs.
Source: FDA drug labels via openFDA
What next?
- Alternatives to aclidinium
- every medicine labeled for the same conditions